204 related articles for article (PubMed ID: 29417755)
1. Safety signal detection and evaluation in clinical development programs: A case study of tofacitinib.
Dasic G; Jones T; Frajzyngier V; Rojo R; Madsen A; Valdez H
Pharmacol Res Perspect; 2018 Feb; 6(1):. PubMed ID: 29417755
[TBL] [Abstract][Full Text] [Related]
2. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
Mease P; Charles-Schoeman C; Cohen S; Fallon L; Woolcott J; Yun H; Kremer J; Greenberg J; Malley W; Onofrei A; Kanik KS; Graham D; Wang C; Connell C; Valdez H; Hauben M; Hung E; Madsen A; Jones TV; Curtis JR
Ann Rheum Dis; 2020 Nov; 79(11):1400-1413. PubMed ID: 32759265
[TBL] [Abstract][Full Text] [Related]
3. Safety of Tofacitinib in the Treatment of Rheumatoid Arthritis in Latin America Compared With the Rest of the World Population.
Castañeda OM; Romero FJ; Salinas A; Citera G; Mysler E; Rillo O; Radominski SC; Cardiel MH; Jaller JJ; Alvarez-Moreno C; Ponce de Leon D; Castelli G; García EG; Kwok K; Rojo R
J Clin Rheumatol; 2017 Jun; 23(4):193-199. PubMed ID: 28145906
[TBL] [Abstract][Full Text] [Related]
4. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme.
Curtis JR; Lee EB; Kaplan IV; Kwok K; Geier J; Benda B; Soma K; Wang L; Riese R
Ann Rheum Dis; 2016 May; 75(5):831-41. PubMed ID: 25902789
[TBL] [Abstract][Full Text] [Related]
5. Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis.
Clowse ME; Feldman SR; Isaacs JD; Kimball AB; Strand V; Warren RB; Xibillé D; Chen Y; Frazier D; Geier J; Proulx J; Marren A
Drug Saf; 2016 Aug; 39(8):755-62. PubMed ID: 27282428
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.
Cohen SB; Tanaka Y; Mariette X; Curtis JR; Lee EB; Nash P; Winthrop KL; Charles-Schoeman C; Thirunavukkarasu K; DeMasi R; Geier J; Kwok K; Wang L; Riese R; Wollenhaupt J
Ann Rheum Dis; 2017 Jul; 76(7):1253-1262. PubMed ID: 28143815
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies.
Wollenhaupt J; Silverfield J; Lee EB; Curtis JR; Wood SP; Soma K; Nduaka CI; Benda B; Gruben D; Nakamura H; Komuro Y; Zwillich SH; Wang L; Riese RJ
J Rheumatol; 2014 May; 41(5):837-52. PubMed ID: 24692527
[TBL] [Abstract][Full Text] [Related]
8. Tofacitinib 5 mg Twice Daily in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs: A Comprehensive Review of Phase 3 Efficacy and Safety.
Bird P; Bensen W; El-Zorkany B; Kaine J; Manapat-Reyes BH; Pascual-Ramos V; Witcombe D; Soma K; Zhang R; Thirunavukkarasu K
J Clin Rheumatol; 2019 Apr; 25(3):115-126. PubMed ID: 29794874
[TBL] [Abstract][Full Text] [Related]
9. Thromboembolic Safety Reporting of Tofacitinib and Baricitinib: An Analysis of the WHO VigiBase.
Vallejo-Yagüe E; Weiler S; Micheroli R; Burden AM
Drug Saf; 2020 Sep; 43(9):881-891. PubMed ID: 32533433
[TBL] [Abstract][Full Text] [Related]
10. Use of a risk characterisation approach to contextualise the safety profile of new rheumatoid arthritis treatments: a case study using tofacitinib.
Curtis JR; Zhang R; Krishnaswami S; Anisfeld A; Chen Y; Strengholt S; Chen C; Geier J
Clin Rheumatol; 2017 Mar; 36(3):683-688. PubMed ID: 27470086
[TBL] [Abstract][Full Text] [Related]
11. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
Olivera PA; Lasa JS; Bonovas S; Danese S; Peyrin-Biroulet L
Gastroenterology; 2020 May; 158(6):1554-1573.e12. PubMed ID: 31926171
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
Song GG; Choi SJ; Lee YH
Int J Rheum Dis; 2019 Aug; 22(8):1563-1571. PubMed ID: 31211506
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
Wang F; Sun L; Wang S; Davis JM; Matteson EL; Murad MH; Luo F; Vassallo R
Mayo Clin Proc; 2020 Jul; 95(7):1404-1419. PubMed ID: 32499126
[TBL] [Abstract][Full Text] [Related]
14. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials.
Strand V; Ahadieh S; French J; Geier J; Krishnaswami S; Menon S; Checchio T; Tensfeldt TG; Hoffman E; Riese R; Boy M; Gómez-Reino JJ
Arthritis Res Ther; 2015 Dec; 17():362. PubMed ID: 26669566
[TBL] [Abstract][Full Text] [Related]
15. Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study.
Calabrese LH; Abud-Mendoza C; Lindsey SM; Lee SH; Tatulych S; Takiya L; Iikuni N; Soma K; Luo Z; Fleischmann R
Arthritis Care Res (Hoboken); 2020 Mar; 72(3):353-359. PubMed ID: 31207152
[TBL] [Abstract][Full Text] [Related]
16. Adverse drug events associated with 5mg versus 10mg Tofacitinib (Janus kinase inhibitor) twice daily for the treatment of autoimmune diseases: A systematic review and meta-analysis of randomized controlled trials.
Huang F; Luo ZC
Clin Rheumatol; 2019 Feb; 38(2):523-534. PubMed ID: 30242639
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial.
Kremer JM; Kivitz AJ; Simon-Campos JA; Nasonov EL; Tony HP; Lee SK; Vlahos B; Hammond C; Bukowski J; Li H; Schulman SL; Raber S; Zuckerman A; Isaacs JD
Arthritis Res Ther; 2015 Apr; 17(1):95. PubMed ID: 25889308
[TBL] [Abstract][Full Text] [Related]
18. Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program.
Mariette X; Chen C; Biswas P; Kwok K; Boy MG
Arthritis Care Res (Hoboken); 2018 May; 70(5):685-694. PubMed ID: 28941219
[TBL] [Abstract][Full Text] [Related]
19. Risk for Herpes Zoster in Tofacitinib-Treated Rheumatoid Arthritis Patients With and Without Concomitant Methotrexate and Glucocorticoids.
Curtis JR; Xie F; Yang S; Bernatsky S; Chen L; Yun H; Winthrop K
Arthritis Care Res (Hoboken); 2019 Sep; 71(9):1249-1254. PubMed ID: 30295428
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study.
Wollenhaupt J; Lee EB; Curtis JR; Silverfield J; Terry K; Soma K; Mojcik C; DeMasi R; Strengholt S; Kwok K; Lazariciu I; Wang L; Cohen S
Arthritis Res Ther; 2019 Apr; 21(1):89. PubMed ID: 30953540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
